An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)
Phase of Trial: Phase IV
Latest Information Update: 06 Dec 2017
At a glance
- Drugs Ixazomib (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms TOURMALINE MM-6
- Sponsors Takeda Oncology
- 17 Oct 2017 Status changed from not yet recruiting to recruiting.
- 08 Sep 2017 Planned initiation date changed from 31 Aug 2017 to 20 Sep 2017.
- 06 Jun 2017 New trial record